Astellas has restarted clinical trials for a next-generation gene therapy for XLMTM following previous deaths. This move is significant as it could lead to new treatment options and advancements in genetic therapies, which are crucial areas of interest for biotech developers. Watch for further safety data and efficacy results from ongoing trials.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



